Topic Highlight
Copyright ©The Author(s) 2015.
World J Gastroenterol. Oct 14, 2015; 21(38): 10749-10759
Published online Oct 14, 2015. doi: 10.3748/wjg.v21.i38.10749
Table 1 Viral and host markers useful for the management or treatment of chronic hepatitis C
Roles in the Peg-IFN eraRoles in the DAA era
Anti-HCV assayDiagnosis/screeningDiagnosis/screening
HCV-RNA assayDiagnosis/active replicationDiagnosis/active replication
Pre-treatment predictor of response to antiviral treatmentsAssessment of response to treatment
Monitoring antiviral treatment
Assessment of response to treatment
HCV genotypePre-treatment predictor of response to antiviral treatmentsChoosing the most appropriate DAA regimen
HCV Q80K polymorphismNoneSelecting patients with HCV-genotype 1a for the simeprevir plus Peg-IFN regimen
Markers of liver fibrosis (liver biopsy/non-invasive methods)Staging of liver diseaseStaging of liver disease
Pre-treatment predictors of response to antiviral treatmentsSelecting the patients with urgency for DAA-based treatment
IL-28B polymorphismPre-treatment predictor of response to antiviral treatmentsPre-treatment predictor of response only in Peg-IFN-based regimens
ITPA polymorphismPre-treatment predictive factor of hemolytic anemia during ribavirin-based regimenIndicator of risk/benefit of using ribavirin in a DAA-based regimen